Rituximab as a first-line treatment in pediatric neuromyelitis optica spectrum disorder

被引：5
|
作者：
Olivieri, Giorgia [1 ]
Nociti, Viviana [2 ,3 ]
Iorio, Raffaele [2 ]
Stefanini, Maria Chiara [1 ]
Losavio, Francesco Antonio [2 ]
Mirabella, Massimiliano [2 ]
Mariotti, Paolo [1 ]
机构：
[1] Catholic Univ, Unit Child Neuropsychiat, Rome, Italy
[2] Catholic Univ, Inst Neurol, Dept Geriatr Neurosci & Orthoped, I-00168 Rome, Italy
[3] Don C Gnocchi Fdn Onlus, Milan, Italy
来源：
NEUROLOGICAL SCIENCES | 2015年 / 36卷 / 12期
关键词：
Pediatric NMOSD; Aquaporin-4; Rituximab; First-line therapy;
D O I：
10.1007/s10072-015-2368-x
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：2301 / 2302
页数：2
相关论文
共 50 条
  • [31] Extensive Neuromyelitis Optica Spectrum Disorder at First Presentation
    Feng, Tanya L.
    Plecash, Alyson
    Chen, Tychicus
    CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 2022, 49 (03) : 428 - 430
  • [32] Neuromyelitis optica spectrum disorder and rituximab: a multi-center analysis
    Novi, G.
    Capobianco, M.
    Gallo, F.
    Mataluni, G.
    Signori, A.
    Laroni, A.
    Annovazzi, P.
    Buttari, F.
    Rossi, S.
    Zuliani, L.
    Sica, F.
    Cocco, E.
    Benedetti, L.
    Malucchi, S.
    Frau, J.
    Sperli, F.
    Sormani, M. P.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 436 - 436
  • [33] Efficacy and Safety of Rituximab in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder
    Ongphichetmetha, Tatchaporn
    Jitprapaikulsan, Jiraporn
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (09) : NP3 - NP4
  • [34] Rituximab De-escalation in Patients With Neuromyelitis Optica Spectrum Disorder
    Demuth, Stanislas
    Collongues, Nicolas
    Audoin, Bertrand
    Ayrignac, Xavier
    Bourre, Bertrand
    Ciron, Jonathan
    Cohen, Mikael
    Deschamps, Romain
    Durand-Dubief, Francoise
    Maillart, Elisabeth
    Papeix, Caroline
    Ruet, Aurelie
    Zephir, Helene
    Marignier, Romain
    De Seze, Jerome
    NEUROLOGY, 2023, 101 (04) : E438 - E450
  • [35] Efficacy and safety of rituximab in multiple sclerosis and neuromyelitis optica spectrum disorder
    Tatchaporn Ongphichetmetha
    Jiraporn Jitprapaikulsan
    Sasitorn Siritho
    Natthapon Rattanathamsakul
    Thammachet Detweeratham
    Naraporn Prayoonwiwat
    Scientific Reports, 14
  • [36] Effectiveness of Rituximab and Oral Immunosuppressive Therapies in Neuromyelitis Optica Spectrum Disorder
    Abou, Widad
    Dresser, Laura
    Javed, Adil
    ANNALS OF NEUROLOGY, 2022, 92 : S138 - S138
  • [37] A Case of Pediatric Neuromyelitis Optica Spectrum Disorder (First Case Reported in Kingdom of Bahrain)
    Malalla, Husain
    Khalil, Ayman
    BAHRAIN MEDICAL BULLETIN, 2021, 43 (02) : 528 - 530
  • [38] Neuromyelitis optica spectrum disorder and Rituximab: a multi-center analysis
    Novi, G.
    Capobianco, M.
    Gallo, F.
    Mataluni, G.
    Signori, A.
    Laroni, A.
    Annovazzi, P.
    Buttari, F.
    Rossi, S.
    Zuliani, L.
    Sica, F.
    Cocco, E.
    Benedetti, L.
    Frau, J.
    Malucchi, S.
    Sperli, F.
    Sormani, M. P.
    EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 : 677 - 677
  • [39] Efficacy and safety of rituximab in multiple sclerosis and neuromyelitis optica spectrum disorder
    Ongphichetmetha, Tatchaporn
    Jitprapaikulsan, Jiraporn
    Siritho, Sasitorn
    Rattanathamsakul, Natthapon
    Detweeratham, Thammachet
    Prayoonwiwat, Naraporn
    SCIENTIFIC REPORTS, 2024, 14 (01)
  • [40] Spectrum of Pediatric Neuromyelitis Optica
    Moodley, M.
    Hong, S. B.
    ANNALS OF NEUROLOGY, 2012, 72 : S205 - S205
12345